Meet the faculty

The Program Directors

Professor Michael McClung

Oregon Osteoporosis Center, Portland, OR, USA

Professor Michael McClung is the Founding Director of the Oregon Osteoporosis Center, USA. He graduated from Rice University in Houston and from the University of Texas Southwestern Medical School in Dallas. After his training in Internal Medicine at Parkland Hospital in Dallas, he completed a Fellowship in Endocrinology at the National Institutes of Health in Bethesda. He was actively involved in the training of young physicians while previously on the Faculty at the Oregon Health & Science University and in the Department of Medical Education at Providence Portland Medical Center.

At the Oregon Osteoporosis Center, Professor McClung has been the Principal Investigator in many clinical trials evaluating the effects of therapeutic agents for osteoporosis and the utility of tests for diagnosis and monitoring of that disease. He serves on the Editorial Board of several journals, is active in numerous professional organizations and has published many scientific articles and book chapters.

Disclosures: Professor McClung has provided consultancy services for Amgen and Merck.

Professor Stuart Ralston

Centre for Genomic and Experimental Medicine, Edinburgh, UK

Professor Stuart H Ralston graduated in Medicine from Glasgow University in 1978 and underwent higher medical training in General Internal Medicine and Rheumatology. He previously held the Chair of Medicine and Bone Metabolism at the University of Aberdeen, and moved to Edinburgh University in 2005 where he now holds the Arthritis Research UK Chair of Rheumatology. He is Academic Director of Edinburgh Clinical Trials Unit and Director of Edinburgh University’s online distance learning MSc in clinical trials. Professor Ralston holds an Honorary Consultant Rheumatologist position with NHS Lothian where he is Clinical Lead for the osteoporosis service and Clinical Director of the rheumatology service. Professor Ralston has researched widely on the molecular and genetic basis of osteoporosis and other bone and joint diseases. He has a special interest in the pathogenesis and management of Paget’s disease of bone. He is joint Editor-in-Chief of Calcified Tissue International and an Editor of Davidson’s Principles and Practice of Medicine. Professor Ralston currently chairs the Commission for Human Medicines for the Medicines and Healthcare Regulatory Authority of the UK.

Disclosures: Professor Ralston has had research contracts with Amgen, Eli Lilly and Ultragenyx, and has provided consultancy services for Novartis

The International Advisory Committee

Professor Ben-Hur Albergaria

Federal University of Espirito Santo, Espirito Santo, Brazil

Professor Ben-Hur Albergaria is a graduate of Federal University of Espirito Santo’s Medical School. He completed postgraduate medical training at Federal University of São Paulo (Brazil). Currently, he is Professor of Clinical Epidemiology at the Federal University of Espirito Santo (Brazil) and Director of Espirito Santo Research and Osteoporosis Center (CEDOES). He is a consultant in osteoporosis and supervisor/interpreter of bone density studies at his center, and a principal investigator for the center’s osteoporosis clinical trials. Professor Albegaria has authored many scientific publications on osteoporosis and bone densitometry.

Professor Albergaria is Past-President of the National Committee of Osteoporosis and Brazilian Society of Gynecology and Obstetrics. He is a faculty member for the International Society of Clinical Densitometry educational programs in bone densitometry and a Fellow of the Brazilian Society of Gynecology and Obstetrics, Brazilian Association of Osteometabolism and Bone Health (ABRASSO) and International Society of Clinical Densitometry.

Disclosures: Professor Albergaria has participated in clinical studies subsidized by Merck & Co., Novartis, Organon, Amgen, Roche and Sanofi-Aventis.

Professor Jacques P Brown

Université Laval, Québec, Canada

Professor Jacques P Brown is a Rheumatologist and a Canadian authority in metabolic bone diseases. He is a Clinical Professor at the Faculty of Medicine, Université Laval and a Clinical Researcher at the CHU de Québec-Université Laval Research Centre. He is a Director for the Canadian Multicentre Osteoporosis Study and the Principal Investigator of the Recognizing Osteoporosis and its Consequences in Quebec Programme.

Professor Brown has received the John B Johnson Award twice from The Paget Foundation for his outstanding contribution to Paget’s disease of bone research and was awarded the Lindy Fraser Memorial Award from Osteoporosis Canada for his leadership and dedication to the ‘2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada’. In 2009, he was decorated as a Knight of the Ordre National du Québec, the highest distinction awarded by the Québec government.

Disclosures: Professor Brown has had research contracts with AbbVie, Amgen, Eli Lilly, Novartis and Takeda. He has also provided consultancy services for Amgen, Eli Lilly, Radius and Rengeneron, and is on the speakers bureau for Amgen and Eli Lilly.

Professor Fidencio Cons Molina

Centro de Investigación en Artritis y Osteoporosis, Mexicali, Mexico

Professor Fidencio Cons Molina is a Rheumatologist dedicated to teaching, clinical attendance and research work. Professor Cons Molina has been involved in clinical research in osteoporosis and rheumatic diseases, and is an internationally recognized expert in the fields of osteoporosis and bone density testing. He is the Founding Director of the Centro de Investigación en Artritis y Osteoporosis, located in a border Mexico–USA community. His Center has been involved in clinical trials of the medications now used to treat osteoporosis.

Professor Cons Molina has published more than 30 papers and book chapters. He is an active member of several international societies focusing on bone diseases and their treatment, as well as chairing the Ibero-American Panel of the International Society for Clinical Densitometry and an international speaker in bone densitometry for Ibero-American countries. He is as a member and Founder of the Asociación Mexicana de Metabolismo Oseo y Mineral, and has served as chairman of the Bone Densitometry Certification Course for the past 10 years. He also serves as representative for Mexico at the IOF-Regional Advisory Council.

Disclosures: Professor Cons Molina declares no competing interests.

Professor Şansın Tüzün

Istanbul University, Istanbul, Turkey

Professor Şansın Tüzün was awarded her Medical Degree from Istanbul University in 1987, where she also specialized in the physical therapy and rehabilitation field, and completed her academic degree in 2003. She is currently Head of the Department of Physical Medicine and Rehabilitation at Istanbul University, Cerrahpasa School of Medicine. In addition to her activities as a clinician and academic teacher, Professor Tüzün is involved with several national and international research studies evaluating new treatments and epidemiology for both osteoporosis and osteoarthritis. She is the author of 65 national and international articles and has published 35 abstracts mainly related to this field.

Professor Tüzün is General Secretary of the Osteoporosis Patient Society of Turkey and has been a Representative Member of the International Osteoporosis Foundation (IOF) since 2007. She is also a Founding Member of the Turkish Osteoporosis Society and coordinated the country-wide epidemiological study, FRACTURK, supported by the Turkish Osteoporosis Society. Following this study regarding hip fracture incidence, she adapted FRAX®into Turkish. She was honored with the IOF President’s Award in 2015.

Disclosures: Professor Tüzün declares no competing interests.

Professor Nelson Watts

Mercy Health, Cincinnati, OH, USA

Professor Nelson Watts currently serves as the Director of Osteoporosis and Bone Health Services for Mercy Health, an integrated health system in Cincinnati, Ohio. He has a long career in osteoporosis research at Emory University and the University of Cincinnati. He has served as President of the American College of Endocrinology, President of the International Society of Clinical Densitometry, Chair of the FDA’s Advisory Committee for Endocrine and Metabolic Drugs and on the ABIM subspecialty board in Endocrinology and Metabolism.

He is active in numerous professional organizations and serves on several Editorial Boards. He has published numerous, books, book chapters, abstracts and articles in journals such as the New England Journal of Medicine and the Journal of the American Medical Association.

Disclosures: Professor Watts has had research contracts with Shire. He has also provided consultancy services for AbbVie, Amgen, Janssen, Merck, Radius and Sanofi. He is a speaker for Amgen and Shire.